Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Apr;95(4):1891–1896. doi: 10.1172/JCI117870

Detection and expression of a cDNA clone that encodes a polypeptide containing two inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera.

N Després 1, G Talbot 1, B Plouffe 1, G Boire 1, H A Ménard 1
PMCID: PMC295733  PMID: 7706496

Abstract

RA is the most frequent and most destructive inflammatory arthropathy. Rheumatoid factors, in spite of their lack of disease specificity, are important serological markers for RA and appear important in its immunopathogenesis as well. In search of more disease-specific autoimmune systems, we have screened a human placenta lambda gt11 cDNA expression library using selected sera from patients with classical erosive RA. We have identified one clone (RA-1) that is recognized by three of five screening sera. The 950-bp insert shows a complete nucleotide sequence homology to the cDNA encoding the two COOH-terminal domains of calpastatin. The deduced open reading frame of the RA-1 cDNA predicts a 284-amino acid protein, with a calculated mol wt of 35.9 kD. Calpastatin is the natural inhibitor of calpains, which are members of the cysteine proteinases recently implicated in joint destruction in rheumatic diseases. The two domains encoded by the RA-1 clone each contain the structural features associated with the inhibitory activity of human calpastatin. By Western blotting, 45.5% or 21/44 RA sera specifically recognized both the fusion and the cleaved recombinant protein. This is in contrast to 4.7% (2/43) in nonrheumatoid sera and 0/10 in normal sera. Anticalpastatin autoantibodies could represent a disease-associated marker in chronic erosive arthritis of the rheumatoid type and could hypothetically play a dual pathogenic role, directly via an immune interference and indirectly through an immune complex mechanism.

Full text

PDF
1891

Images in this article

1893Image
on p.1893
1893Image
on p.1893

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  2. Asada K., Ishino Y., Shimada M., Shimojo T., Endo M., Kimizuka F., Kato I., Maki M., Hatanaka M., Murachi T. cDNA cloning of human calpastatin: sequence homology among human, pig, and rabbit calpastatins. J Enzyme Inhib. 1989;3(1):49–56. doi: 10.3109/14756368909030363. [DOI] [PubMed] [Google Scholar]
  3. Burman K. D., Baker J. R., Jr Immune mechanisms in Graves' disease. Endocr Rev. 1985 Spring;6(2):183–232. doi: 10.1210/edrv-6-2-183. [DOI] [PubMed] [Google Scholar]
  4. Croall D. E., DeMartino G. N. Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol Rev. 1991 Jul;71(3):813–847. doi: 10.1152/physrev.1991.71.3.813. [DOI] [PubMed] [Google Scholar]
  5. Dean D. D., Martel-Pelletier J., Pelletier J. P., Howell D. S., Woessner J. F., Jr Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest. 1989 Aug;84(2):678–685. doi: 10.1172/JCI114215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Després N., Boire G., Lopez-Longo F. J., Ménard H. A. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol. 1994 Jun;21(6):1027–1033. [PubMed] [Google Scholar]
  7. Emori Y., Kawasaki H., Imajoh S., Minami Y., Suzuki K. All four repeating domains of the endogenous inhibitor for calcium-dependent protease independently retain inhibitory activity. Expression of the cDNA fragments in Escherichia coli. J Biol Chem. 1988 Feb 15;263(5):2364–2370. [PubMed] [Google Scholar]
  8. Esser R. E., Angelo R. A., Murphey M. D., Watts L. M., Thornburg L. P., Palmer J. T., Talhouk J. W., Smith R. E. Cysteine proteinase inhibitors decrease articular cartilage and bone destruction in chronic inflammatory arthritis. Arthritis Rheum. 1994 Feb;37(2):236–247. doi: 10.1002/art.1780370213. [DOI] [PubMed] [Google Scholar]
  9. Fukui I., Tanaka K., Murachi T. Extracellular appearance of calpain and calpastatin in the synovial fluid of the knee joint. Biochem Biophys Res Commun. 1989 Jul 31;162(2):559–566. doi: 10.1016/0006-291x(89)92347-4. [DOI] [PubMed] [Google Scholar]
  10. Gabrijelcic D., Annan-Prah A., Rodic B., Rozman B., Cotic V., Turk V. Determination of cathepsins B and H in sera and synovial fluids of patients with different joint diseases. J Clin Chem Clin Biochem. 1990 Mar;28(3):149–153. doi: 10.1515/cclm.1990.28.3.149. [DOI] [PubMed] [Google Scholar]
  11. Hoet R. M., Boerbooms A. M., Arends M., Ruiter D. J., van Venrooij W. J. Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann Rheum Dis. 1991 Sep;50(9):611–618. doi: 10.1136/ard.50.9.611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Huet G., Flipo R. M., Colin C., Janin A., Hemon B., Collyn-d'Hooghe M., Lafyatis R., Duquesnoy B., Degand P. Stimulation of the secretion of latent cysteine proteinase activity by tumor necrosis factor alpha and interleukin-1. Arthritis Rheum. 1993 Jun;36(6):772–780. doi: 10.1002/art.1780360606. [DOI] [PubMed] [Google Scholar]
  13. Huet G., Flipo R. M., Richet C., Thiebaut C., Demeyer D., Balduyck M., Duquesnoy B., Degand P. Measurement of elastase and cysteine proteinases in synovial fluid of patients with rheumatoid arthritis, sero-negative spondylarthropathies, and osteoarthritis. Clin Chem. 1992 Sep;38(9):1694–1697. [PubMed] [Google Scholar]
  14. Jackson J. Autoantibody-facilitated proteolytic cleavage: a new pathogenic mechanism in autoimmunity. Biochem Soc Trans. 1991 Feb;19(1):176–180. doi: 10.1042/bst0190176. [DOI] [PubMed] [Google Scholar]
  15. Lenarcic B., Gabrijelcic D., Rozman B., Drobnic-Kosorok M., Turk V. Human cathepsin B and cysteine proteinase inhibitors (CPIs) in inflammatory and metabolic joint diseases. Biol Chem Hoppe Seyler. 1988 May;369 (Suppl):257–261. [PubMed] [Google Scholar]
  16. McCachren S. S. Expression of metalloproteinases and metalloproteinase inhibitor in human arthritic synovium. Arthritis Rheum. 1991 Sep;34(9):1085–1093. doi: 10.1002/art.1780340904. [DOI] [PubMed] [Google Scholar]
  17. Naparstek Y., Plotz P. H. The role of autoantibodies in autoimmune disease. Annu Rev Immunol. 1993;11:79–104. doi: 10.1146/annurev.iy.11.040193.000455. [DOI] [PubMed] [Google Scholar]
  18. Opdenakker G., Van Damme J. Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. Cytokine. 1992 Jul;4(4):251–258. doi: 10.1016/1043-4666(92)90064-x. [DOI] [PubMed] [Google Scholar]
  19. Prchal J. T., Morley B. J., Yoon S. H., Coetzer T. L., Palek J., Conboy J. G., Kan Y. W. Isolation and characterization of cDNA clones for human erythrocyte beta-spectrin. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7468–7472. doi: 10.1073/pnas.84.21.7468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Saitta M. R., Keene J. D. Molecular biology of nuclear autoantigens. Rheum Dis Clin North Am. 1992 May;18(2):283–310. [PubMed] [Google Scholar]
  21. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Schönbeck S., Chrestel S., Hohlfeld R. Myasthenia gravis: prototype of the antireceptor autoimmune diseases. Int Rev Neurobiol. 1990;32:175–200. doi: 10.1016/s0074-7742(08)60583-8. [DOI] [PubMed] [Google Scholar]
  23. Sherman MYu, Goldberg A. L. Involvement of the chaperonin dnaK in the rapid degradation of a mutant protein in Escherichia coli. EMBO J. 1992 Jan;11(1):71–77. doi: 10.1002/j.1460-2075.1992.tb05029.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Simon M., Girbal E., Sebbag M., Gomès-Daudrix V., Vincent C., Salama G., Serre G. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. J Clin Invest. 1993 Sep;92(3):1387–1393. doi: 10.1172/JCI116713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Smith D. B., Johnson K. S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene. 1988 Jul 15;67(1):31–40. doi: 10.1016/0378-1119(88)90005-4. [DOI] [PubMed] [Google Scholar]
  26. Squìer M. K., Miller A. C., Malkinson A. M., Cohen J. J. Calpain activation in apoptosis. J Cell Physiol. 1994 May;159(2):229–237. doi: 10.1002/jcp.1041590206. [DOI] [PubMed] [Google Scholar]
  27. Steiner G., Hartmuth K., Skriner K., Maurer-Fogy I., Sinski A., Thalmann E., Hassfeld W., Barta A., Smolen J. S. Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest. 1992 Sep;90(3):1061–1066. doi: 10.1172/JCI115921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Suzuki K., Saido T. C., Hirai S. Modulation of cellular signals by calpain. Ann N Y Acad Sci. 1992 Dec 31;674:218–227. doi: 10.1111/j.1749-6632.1992.tb27490.x. [DOI] [PubMed] [Google Scholar]
  29. Suzuki K., Shimizu K., Hamamoto T., Nakagawa Y., Hamakubo T., Yamamuro T. Biochemical demonstration of calpains and calpastatin in osteoarthritic synovial fluid. Arthritis Rheum. 1990 May;33(5):728–732. doi: 10.1002/art.1780330516. [DOI] [PubMed] [Google Scholar]
  30. Suzuki K., Shimizu K., Hamamoto T., Nakagawa Y., Murachi T., Yamamuro T. Characterization of proteoglycan degradation by calpain. Biochem J. 1992 Aug 1;285(Pt 3):857–862. doi: 10.1042/bj2850857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Tan E. M. Autoantibodies in pathology and cell biology. Cell. 1991 Nov 29;67(5):841–842. doi: 10.1016/0092-8674(91)90356-4. [DOI] [PubMed] [Google Scholar]
  32. Yamamoto S., Shimizu K., Shimizu K., Suzuki K., Nakagawa Y., Yamamuro T. Calcium-dependent cysteine proteinase (calpain) in human arthritic synovial joints. Arthritis Rheum. 1992 Nov;35(11):1309–1317. doi: 10.1002/art.1780351111. [DOI] [PubMed] [Google Scholar]
  33. van de Wiel B. A., Dolman K. M., van der Meer-Gerritsen C. H., Hack C. E., von dem Borne A. E., Goldschmeding R. Interference of Wegener's granulomatosis autoantibodies with neutrophil Proteinase 3 activity. Clin Exp Immunol. 1992 Dec;90(3):409–414. doi: 10.1111/j.1365-2249.1992.tb05860.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES